Srikanth Nagalla, MD

home / authors / srikanth-nagalla-md

Articles

Dr. Nagalla on Efforts to Predict Risk of Thrombosis in Patients With MPNs

Dr. Nagalla on Efforts to Predict Risk of Thrombosis in Patients With MPNs

Srikanth Nagalla, MD
April 25th 2020

Read More

Dr. Nagalla on the Utility of DOACs in Cancer-Associated Thrombosis

Dr. Nagalla on the Utility of DOACs in Cancer-Associated Thrombosis

Srikanth Nagalla, MD
April 18th 2020

Srikanth Nagalla, MD, discusses the utility of direct oral anticoagulants in cancer-associated thrombosis.

Read More

Dr. Nagalla on Need for Timely Assays for DOACs in MPNs

Dr. Nagalla on Need for Timely Assays for DOACs in MPNs

Srikanth Nagalla, MD
March 27th 2020

Srikanth Nagalla, MD, discusses research efforts dedicated to the development of timely assays for direct oral anticoagulants in myeloproliferative neoplasms.

Read More

Dr. Nagalla on Aspirin Use During DOAC Treatment for MPNs

Dr. Nagalla on Aspirin Use During DOAC Treatment for MPNs

Srikanth Nagalla, MD
March 26th 2020

Srikanth Nagalla, MD, discusses aspirin recommendations for patients with myeloproliferative neoplasms who are receiving direct oral anticoagulants.

Read More

Dr. Nagalla on the Challenges of Managing Thrombocytopenia in MPNs

Dr. Nagalla on the Challenges of Managing Thrombocytopenia in MPNs

Srikanth Nagalla, MD
March 16th 2020

Srikanth Nagalla, MD, discusses the challenges of managing thrombocytopenia in patients with myeloproliferative neoplasms.

Read More

Dr. Nagalla on the Utility of DOACs in MPN-Associated Thrombosis

Dr. Nagalla on the Utility of DOACs in MPN-Associated Thrombosis

Srikanth Nagalla, MD
January 22nd 2020

Srikanth Nagalla, MD, discusses the utility of direct oral anticoagulants in patients with a myeloproliferative neoplasm–associated venous thromboembolism.

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need